Hamill Laura

DirectorY-mAbs Therapeutics, Inc. (YMAB) · full profile →Form 4 · filed Sep 19, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
2 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2025Tender(U)6K$8.60$50K0
Sep 16, 2025Disposed to issuer(D)25K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2025Disposed to issuer(D)27K0
Sep 16, 2025Disposed to issuer(D)11K0
Sep 16, 2025Disposed to issuer(D)33K0
Sep 16, 2025Disposed to issuer(D)14K0
Sep 16, 2025Disposed to issuer(D)15K0
Sep 16, 2025Disposed to issuer(D)16K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001751804-25-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly: